ArticleHealth science reports2025
Immunohistochemical Breast Cancer Profiling Among Iraqi Women: Molecular Subtype Classification, Clinicopathology Associations, and Treatment-Decision Making Tools: A Cross-Sectional Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Breast cancer is the most common cause of female cancer-related death in Iraq. This study aimed to classify breast cancer molecular subtypes in the Iraqi population, and investigate the association with clinicopathology parameters, and predict survival outcomes. Methods: This cross-sectional study collected breast cancer samples that included: tumor size, grade, lymph node involvement, and LVI. Cases were stained for estrogen (ER) and progesterone (PR) receptors, HER2, and Ki-67 for IHC subtyping. HER2 score 3 cases were further evaluated by SISH. Molecular profile classification used the St Gallen consensus. The tumor profiles were modelled with treatment combinations using the PREDICT decision making tool of up to 10-year OS outcomes; > 5% differences were deemed clinically relevant. Results: The mean age of patients was 50.16 ± 12.28 years. ER and PR positivity was high (81.8% and 73.7%) relative to HER2 (20.8%). Significant clinicopathology associations occurred between ER expression and tumor type and grade ( Conclusion: St Gallen molecular characterisation of breast tumors is critical for refining triage of healthcare patients in Iraq. Molecular classification using IHC subtypes identified a high prevalence of favorable Luminal-A-like type, and the lowest worldwide rates of poor prognostic TNBC cancer. The use of immunohistochemistry-based cancer subtyping is further strengthened in clinical practice with online prognostication tools that assist the treatment selection process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.